TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an announcement.
Lepu Biopharma Co., Ltd. has announced that its board of directors will hold a meeting on August 20, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The board will also consider recommending the payment of an interim dividend and address other business matters. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential dividend payouts, which could impact investor confidence and market positioning.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on developing and providing innovative pharmaceutical products and services.
Average Trading Volume: 29,539,096
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.78B
See more insights into 2157 stock on TipRanks’ Stock Analysis page.